These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37087783)

  • 1. Several neuropeptides involved in parkinsonian neuroprotection modulate the firing properties of nigral dopaminergic neurons.
    Chen L; Liu C; Xue Y; Chen XY
    Neuropeptides; 2023 Jun; 99():102337. PubMed ID: 37087783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropeptide apelin presented in the dopaminergic neurons modulates the neuronal excitability in the substantia nigra pars compacta.
    Liu C; Kang NW; Wang Y; Xue Y; Chen XY; Chen L
    Neuropharmacology; 2022 Nov; 219():109235. PubMed ID: 36041497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changed firing activity of nigra dopaminergic neurons in Parkinson's disease.
    Chen XY; Liu C; Xue Y; Chen L
    Neurochem Int; 2023 Jan; 162():105465. PubMed ID: 36563966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GLP-1 modulated the firing activity of nigral dopaminergic neurons in both normal and parkinsonian mice.
    Liu C; Liu WH; Yang W; Chen L; Xue Y; Chen XY
    Neuropharmacology; 2024 Jul; 252():109946. PubMed ID: 38599494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
    Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
    Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orexins increase the firing activity of nigral dopaminergic neurons and participate in motor control in rats.
    Liu C; Xue Y; Liu MF; Wang Y; Liu ZR; Diao HL; Chen L
    J Neurochem; 2018 Nov; 147(3):380-394. PubMed ID: 30102759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-Expression of Nogo-A in Dopaminergic Neurons of the Human Substantia Nigra Pars Compacta Is Reduced in Parkinson's Disease.
    Eyer GC; Di Santo S; Hewer E; Andereggen L; Seiler S; Widmer HR
    Cells; 2021 Nov; 10(12):. PubMed ID: 34943877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sparing of orexin-A and orexin-B neurons in the hypothalamus and of orexin fibers in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated macaques.
    Bensaid M; Tandé D; Fabre V; Michel PP; Hirsch EC; François C
    Eur J Neurosci; 2015 Jan; 41(1):129-36. PubMed ID: 25328140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orexin-B exerts excitatory effects on nigral dopaminergic neurons and alleviates motor disorders in MPTP parkinsonian mice.
    Bian K; Liu C; Wang Y; Xue Y; Chen L
    Neurosci Lett; 2021 Nov; 765():136291. PubMed ID: 34666119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.
    Dragicevic E; Poetschke C; Duda J; Schlaudraff F; Lammel S; Schiemann J; Fauler M; Hetzel A; Watanabe M; Lujan R; Malenka RC; Striessnig J; Liss B
    Brain; 2014 Aug; 137(Pt 8):2287-302. PubMed ID: 24934288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GABAergic control of rat substantia nigra dopaminergic neurons: role of globus pallidus and substantia nigra pars reticulata.
    Celada P; Paladini CA; Tepper JM
    Neuroscience; 1999 Mar; 89(3):813-25. PubMed ID: 10199615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GABAergic control of substantia nigra dopaminergic neurons.
    Tepper JM; Lee CR
    Prog Brain Res; 2007; 160():189-208. PubMed ID: 17499115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Representation of spontaneous movement by dopaminergic neurons is cell-type selective and disrupted in parkinsonism.
    Dodson PD; Dreyer JK; Jennings KA; Syed EC; Wade-Martins R; Cragg SJ; Bolam JP; Magill PJ
    Proc Natl Acad Sci U S A; 2016 Apr; 113(15):E2180-8. PubMed ID: 27001837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate.
    Harrison IF; Anis HK; Dexter DT
    Neurosci Lett; 2016 Feb; 614():16-23. PubMed ID: 26742637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
    Porritt MJ; Batchelor PE; Howells DW
    Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cav2.3 channels contribute to dopaminergic neuron loss in a model of Parkinson's disease.
    Benkert J; Hess S; Roy S; Beccano-Kelly D; Wiederspohn N; Duda J; Simons C; Patil K; Gaifullina A; Mannal N; Dragicevic E; Spaich D; Müller S; Nemeth J; Hollmann H; Deuter N; Mousba Y; Kubisch C; Poetschke C; Striessnig J; Pongs O; Schneider T; Wade-Martins R; Patel S; Parlato R; Frank T; Kloppenburg P; Liss B
    Nat Commun; 2019 Nov; 10(1):5094. PubMed ID: 31704946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morpho-Functional Changes of Nigral Dopamine Neurons in an α-Synuclein Model of Parkinson's Disease.
    Ledonne A; Massaro Cenere M; Paldino E; D'Angelo V; D'Addario SL; Casadei N; Nobili A; Berretta N; Fusco FR; Ventura R; Sancesario G; Guatteo E; Mercuri NB
    Mov Disord; 2023 Feb; 38(2):256-266. PubMed ID: 36350188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demystifying the Neuroprotective Role of Neuropeptides in Parkinson's Disease: A Newfangled and Eloquent Therapeutic Perspective.
    Behl T; Madaan P; Sehgal A; Singh S; Makeen HA; Albratty M; Alhazmi HA; Meraya AM; Bungau S
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual effects of L-DOPA on nigral dopaminergic neurons.
    Guatteo E; Yee A; McKearney J; Cucchiaroni ML; Armogida M; Berretta N; Mercuri NB; Lipski J
    Exp Neurol; 2013 Sep; 247():582-94. PubMed ID: 23481547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.